Cameron Durrant, MD, MBA
Executive Chairman of the Board
Dr. Durrant is a medically trained MBA who has a unique entrepreneurial background coupled with major international pharmaceutical and small company CEO experience. Dr. Durrant has held executive positions at major global pharmaceutical companies, including Merck & Co., GlaxoSmithKline and Pharmacia Corporation (now part of Pfizer, Inc.). Most recently, Dr. Durrant spent almost three years as Worldwide Vice President, Infectious Diseases, Global Strategic Marketing at Johnson & Johnson. He has also been CEO of two specialty pharmaceutical companies, PediaMed and Spherics. Dr. Durrant was a regional winner and national finalist for Ernst & Young’s Entrepreneur of the Year award in 2005. He holds a MBA from Henley Management College in Oxford, U.K., a DRCOG from the Royal College of Obstetricians and Gynaecologists in London, U.K., a MRCGP from the Royal College of General Practitioners in London, U.K., a DipCH from the Australian Academy, Melbourne, Australia and an MB and BCh (equivalent to the American MD degree) from the Welsh National School of Medicine in Cardiff, U.K.

Alison Ayers, M.Sc.
Director
Ms. Ayers is currently the Worldwide Commercial Head for Oncology at Pfizer (NYSE: PFE), with responsibility for Pfizer’s oncology portfolio, which includes more than 20 drug candidates in clinical development, as well as lifecycle optimization for their leading oncology treatments including Sutent. In addition, she is a member of the leadership team that develops Pfizer’s oncology strategic plan and which manages the portfolio, including asset prioritization, development planning, strategic and investment decisions including licensing and acquisitions. She is also responsible for the commercial strategy for Pfizer’s oncology department, which had sales of over $2 billion in 2007. She holds a Master of Science with distinction in biopharmacy and a Diploma in Business Studies, both from the University of London, UK, as well as a Bachelor of Science with honors in physiology and biochemistry from the University of Southampton, UK.

David L. Tousley, CPA, MBA
Director
Mr. Tousley is an accomplished professional with over 25 years of senior-level experience in biotech, specialty pharmaceuticals and full-phase pharmaceutical companies. He is currently serving as a financial consultant specializing in strategic planning and management, corporate governance and business development. He has held the position of President, COO and CFO at companies including airPharma, PediaMed Pharmaceuticals, AVAX Technologies, and Pasteur, Merieux, and Connaught (known today as Sanofi-Pasteur). During his career, Mr. Tousley has led all aspects of operations, including pharmaceutical development, in both the private and public company environment. His accomplishments include the raising over $90 million in debt and equity financings and he has led key business development activities, including joint ventures, partnerships, acquisitions and divestitures in the U.S., Europe and Australia. Mr. Tousley holds an MBA in accounting from Rutgers Graduate School of Business and a B.A. in English from Rutgers College, both in New Jersey.

Harvey Lalach
President, CFO, Secretary and Director
For the past 21 years, Harvey Lalach has been involved in various aspects of the securities industry. From 1986 through to 1997, he held various roles in financial institutions such as TD Bank and BMO Nesbitt Burns. For the past 10 years, Mr. Lalach has focused exclusively on the operation and administration of numerous start-up American and Canadian public companies, serving in both Director and Officer capacities. Mr. Lalach has extensive experience in the management and governance of publicly listed companies.